Ding et al. [15] reported that the depot GnRH agonist protocol could improve endometrial receptivity and the clinical pregnancy rate, but it also increased the OHSS risk, consistent with our results. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.